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ABSTRACT
Objective: The aim of this study was to prospectively evaluate the efficacy of a therapeutic course
of intravenous antibiotics followed by oral antibiotics vs. intravenous antibiotics alone to prevent
recurrent urinary tract infection.
Methods: Pyelonephritis was documented by strict criteria in 67 pregnant women who were then
treated with appropriate intravenous antibiotics until afebrile and asymptomatic for 48 h. Women
were then randomized to completion of a 10-day course of oral nitrofurantoin 100 mg qid or no
further antibiotic therapy. Urine cultures (UC) were obtained 2 and 6 weeks after discharge, and
at delivery. A positive UC or readmission for pyelonephritis was considered endpoints for partici-
pation in the study. Antibiotic suppression was not used.
Results: Readmission for pyelonephritis prior to the 2-week follow-up visit occurred in 2/36
(5.6%) women randomized to the oral therapy group compared to 4/31 (12.9%) in the no oral
treatment group (P 0.29). At the 2-week follow-up visit, 6/31 (19.4%) women had a positive UC
in the oral therapy compared to 8/26 (30.1%) in the no oral treatment group but this difference was
not statistically significant (P 0.31).
Conclusions: Completion of 10 days of antibiotic therapy with oral medication does not signifi-
cantly reduce the risk ofrecurrent pyelonephritis immediately post-parenteral treatment. Women in
the no oral treatment group had a non-significant increase in positive UC at the 2-week follow-up
visit. The high rates of recurrent urinary tract infection during pregnancy in both groups under-
score the need for regular UC and for the possible role of oral antibiotic suppression. Infect. Dis.
Obstet. Gynecol. 4:294-297, 1996. (C) 1997 Wiley-Liss, Inc.
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yelonephritis during pregnancy is a serious
complication that often results in significant
maternal and neonatal morbidity. The treatment
of antenatal pyelonephritis typically includes a
course of parenteral antibiotics until the patient
becomes asymptomatic followed by oral antibiotics
to complete a 10-14-day antibiotic regimen.
Completion of oral therapy depends on the com-
pliance of the patient. If women with antenatal
pyelonephritis could be managed as effectively
with only parenteral antibiotics until afebrile and
asymptomatic for 48 h, this would result not only in
a potential cost savings, but possibly would also
circumvent the compliance issue entirely.
We propose to evaluate the effectiveness of par-
enteral therapy alone against the more traditional
regimen which includes a follow-up course of oral
antibiotics to prevent recurrent pyelonephritis and
*Correspondence to: Dr. Brian C. Brost, Department of Obstetrics and Gynecology, 171 Ashley Avenue, Charleston, SC
29425.
Clinical Study
Received 15 August 1996
Accepted 14 January 1997ANTENATAL PYELONEPHRITIS ANTIBIOTIC THERAPY BROST ET AL.
asymptomatic urinary tract infections. Close sur-
veillance of urine cultures after completion of an-
tibiotic therapy was chosen instead of using antibi-
otic suppression as was suggested by Lenke et al.e
This management protocol allows us to more ad-
equately evaluate the early and late infectious se-
quelae of the proposed antibiotic regimens.
SUBJECTS AND METHODS
During the study period (August 1990 to Decem-
ber 1994), women admitted for antepartum pyelo-
nephritis at the Medical University of South Caro-
lina were screened for protocol eligibility. Study
entry requirements were based on a strict set of
screening diagnostic criteria including an admission
oral temperature >38.0C, costovertebral angle
tenderness, and a positive urine culture (UC) with
>10s colony forming units (CFU) of a pathogenic
urinary organism obtained prior to initiation of an-
tibiotic therapy. Exclusion criteria included evi-
dence of a renal abscess, a prior episode of pyelo-
nephritis during the index pregnancy, and women
not exhibiting all of the inclusion criteria.
The initial antibiotic regimen was determined
by the attending physician. Antibiotic therapy was
continued until the patient was asymptomatic on
physical examination and was afebrile (tempera-
ture <38.0C) for at least 48 h. Patients were ap-
proached prior to completion of intravenous anti-
biotic therapy about participation in our study pro-
tocol and randomized after obtaining written
consent. Repeat UCs were not obtained prior to
discharge from the hospital. The study protocol
was approved by the Institutional Review Board at
our facility.
Patients entering the protocol were randomized
into one of two treatment groups by a coin-flip
table established at the beginning of the study.
Women in the first group received a total of 10 days
of antibiotic therapy (intravenous followed by oral
nitrofurantoin 100 mg qid), while the other group
of women received no further antibiotic therapy
after completion of intravenous therapy. Women
enrolled in the study were followed for evidence of
reinfection until their delivery. Clean catch UCs
were obtained at 2 and 6 weeks after discharge
from the hospital and again at delivery. Recurrent
pyelonephritis or a positive UC after documented
cure was considered signs of reinfection. No sup-
pressive antibiotic therapy was used in any of the
study patients. Women were removed from the
study at the time of any positive UC or episode of
recurrent pyelonephritis. At that point, they were
retreated with appropriate antibiotic therapy and
placed on antibiotic suppression.
The data obtained were analyzed using a two-
tailed Student’s t-test for comparison of means and
chi-square analysis or Fisher’s exact test as appro-
priate for evaluation of categorical variables. Values
were considered statistically significant at P < 0.05.
Power calculations performed after the data were
collected and before the data were analyzed
showed that 31 women would be needed in each
group to show a 35% difference in recurrent urinary
tract infections at an alpha of 0.05 and a beta of 0.2.
RESULTS
During the study period, all pregnant women ad-
mitted with the diagnosis of antenatal pyelonephri-
tis were screened for study participation. All 67
women meeting the entry criteria agreed to partici-
pate. The oral therapy group was comprised of 36
women, and 31 were randomized to receive no fur-
ther oral antibiotic therapy. The admission demo-
graphics (mean _+ SD) including maternal age, eth-
nic composition, estimated gestational age on ad-
mission, maternal temperature on admission, white
blood cell count on admission, urinary pathogen,
antibiotic therapy, and days on intravenous antibi-
otics were similar between the two groups (Ta-
ble 1).
During the 2-week interval after discharge from
the hospital, readmission for acute pyelonephritis
occurred in 2/36 (5.6%) of the women randomized
to oral therapy and 4/31 (12.9%) of the women in
the no oral treatment group (P 0.29). Delivery
also occurred in 4 patients prior to the 2-week cul-
ture. In these 4 women there was a positive UC in
1, a negative UC in 2, and no culture obtained in 1.
At the 2-week evaluation, a positive UC was noted
in 6/31 (19.4%) and 8/26 (30.1%) of the women in
the oral therapy and no oral treatment groups, re-
spectively (P 0.31). Combining the positive UC
results to the readmissions for pyelonephritis, a to-
tal of 9/36 (25.0%) women in the oral therapy group
and 12/31 (38.7%) women in the no oral therapy
group had evidence of reinfection within 2 weeks
of initial intravenous therapy for antenatal pyelo-
nephritis (P 0.22).
During the remainder of the pregnancy, pyelo-
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TABLE I. Maternal admission characteristics and
hospital course
Oral No further
antibiotics therapy
(n 36) (n 31)
Age (years) 22.7 + 5.04 21.5 + 4. II NS
Race
White 28 (77.8%) 17 (54.8%) NS
Black 7 (I 9.4%) 12 (38.7%) NS
Other (2.8%) 2 (6.5%) NS
EGA at admission (weeks) 21.9 + 7.75 24.9 + 6.76 NS
Range (weeks) (9.0-38. I) (I 0.7-38.6)
Temperature on
admission (C) 38.9 + 0.56 39. + 0.62 NS
WBC on admission 13.4 + 3.96 14.2 + 4.14 NS
Organism
Escherichia coli 32 (88.9%) 26 (83.9%) NS
Proteus 0 1(3.2%) NS
Klebsiella 3 (8.3%) (3.2%) NS
Enterobacter 0 1(3.2%) NS
Other (2.8%) 2 (6.5%) NS
Antiobiotic therapy
Cefazolin 26 (72.2%) 22 (71.0%) NS
Cefazolin/gentamicin 7 (19.4%) 5 (I 6. I%) NS
Cefazolin/other 2 (5.6%) 2 (6.5%) NS
Ampicillin/gentamicin 1(2.8%) 1(3.2%) NS
Other 0 1(3.2%) NS
Days IV antibiotics 4.5 + 2.46 4.6 + 1.69 NS
EGA at delivery (weeks) 38.2 + 3.45 38.8 + 2.50 NS
Range (weeks) (17.1-41.4) (34.3-41.3)
aNS, not statistically significant; EGA, estimated gestational age; WBC,
white blood cell count; IV, intravenous.
nephritis recurred in 2 more women in the oral
therapy group and in the no oral treatment group.
Positive UCs following the initial 2-week check
were noted in 6/36 (16.7%) women in the oral
therapy group and 2/31 (6.5%) in the no oral treat-
ment group. The organisms grown on UC from the
initial admission for pyelonephritis and each sub-
sequent episode of urinary tract infection were
similar in all cases obtained (9/12). On 3 of the
recurrent admissions, the UC failed to grow an or-
ganism or was not obtained. These women exhib-
ited all the classical signs and symptoms of pyelo-
nephritis and were treated as infected.
DISCUSSION
In this study, it appears that the combination of
parenteral antibiotics followed by a O-day course
of oral antibiotics for 10 days does not significantly
reduce the short-term risk of recurrent pyelone-
phritis and urinary tract infection. Long term, the
total number of episodes of recurrent infection af-
ter admission for pyelonephritis was similar in both
groups through delivery (47.2% vs. 48.4% in the
oral therapy and no oral therapy groups, respec-
tively). However, with review of the entire study
group throughout pregnancy, two trends become
apparent (Fig. 1). The majority of the cases of py-
elonephritis (4/5) and positive UCs (8/10) in
women receiving parenteral therapy only occurs
within 2 weeks of discharge. In contrast, the group
receiving a 10-day course of oral antibiotics had a
higher rate of recurrent infection after the initial
2-week culture check.
These findings lead one to consider two impor-
tant points: 1) the treatment of pyelonephritis dur-
ing pregnancy may require more aggressive therapy
(a longer intravenous antibiotic course than until
asymptomatic and afebrile for 48 h) given the num-
ber of positive cultures and readmissions for pyelo-
nephritis noted in both groups, and 2) the impor-
tance of close surveillance for recurrent or persis-
tent urinary tract infection as suggested by Lenke
et al. e
One other study by Faro et al.3 addresses the
issue of treating antenatal pyelonephritis with par-
enteral antibiotics alone. Women were treated with
cefuroxime for a minimum of 5 days and until they
were clinically asymptomatic and afebrilc for more
than 72 h. Of the 23 patients enrolled in the study
with antenatal pyelonephritis, 12 (52%) were con-
sidered both a clinical and bacteriologic cure by
negative culture results at 2-3 weeks after dis-
charge. The other women were classified either as
colonized (6/23) or lost to follow-up (5/23). Their
rates of recurrent or "colonized" urinary tract in-
fections were similar to the findings of women not
treated with oral antibiotics in our study.
The patient return rate in our study is typical of
a lower socioeconomic clinic population with about
1/3 of the women enrolled in the study not return-
ing for their 2-week culture check (9 women in the
no oral therapy group and 8 women in the oral
therapy group). While these numbers seem el-
evated, only 5 women had no recurrent urinary
tract disease or UC obtained through the remainder
of their pregnancies (3 in the no oral therapy group
and 2 in the oral therapy group). This fact would
also call into question the compliance of women in
the oral antibiotic treatment group. It is possible
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Fig. I. UC results and timing of recurrent urinary tract infection.
that some of the early recurrent infections in the
oral therapy group could represent women who
were non-compliant in completing their course of
nitrofurantoin.
While the use of parenteral antibiotics was suc-
cessful in treating antenatal pyelonephritis, those
women not started on a course of subsequent oral
antibiotics showed a trend toward early recurrence
of urinary tract infection. However, a course of in-
travenous and oral antibiotic therapy does not sig-
nificantly reduce the risk of recurrent pyelonephri-
tis in the 2 weeks following discharge from the
hospital. The high rates of recurrent urinary tract
infection during pregnancy in both groups under-
score the need for regular follow-up with UC or
possible oral antibiotic suppression throughout
pregnancy.
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